Our Mission
The Radiation Oncology Branch (ROB) exists to plan and conduct pre-clinical and clinical research on the biologic and therapeutic effects of radiation administrated alone or in combination with other modalities of treatment; to develop novel technology and imaging based approaches for radiation oncology; to investigate the natural history of disease to understand and evaluate means of diagnostic assessment for the purpose of optimizing treatment selections; and to provide radiation therapy as well as general oncology consultations for patients admitted to other NIH Clinical Research Center (CRC) clinical services, in a collaborative approach.
Clinical Research Overview
The Radiation Oncology Branch exists as part of the National Cancer Institute (NCI) Center for Cancer Research (CCR). The ROB designs and conducts pre-clinical and clinical research on the biologic and therapeutic effect of radiation therapy. The research clinical trials that the ROB develops and conducts involve novel technology and/or imaging based approaches to radiation therapy treatment. Within ROB Computer Tomography (CT) and Magnetic Resonance (MR) image fusion is a routine part of a patient treatment planning. The ROB also provides treatment via radiosurgery, intensity-modulated 3-D conformal radiotherapy (IMRT), real-time dose measurement, brachytherapy, and MR-guided procedures.
The ROB team of clinical investigators are board certified in radiation oncology. The ROB clinical team is comprised of radiation oncologists, physicists, dosimetrists, residents, research nurses, clinical staff nurses, clinical assistants, data managers and access to social workers. All of our staff have board certification or professionally appropriate certification and education for their field of expertise. As a team, the ROB is dedicated to conducting clinical trials based on sound translations research, while providing the highest possible clinical care for patients with various types of malignancies.
The ROB clinical staff collaborate with other clinical and laboratory investigators within the ROB, CCR, as well as other Institutes within the NIH, including National Heart Lung and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the National Institute on Aging (NIA). The ROB also provides consultative services to the entire CCR, collaborating with other clinical services to provide the most comprehensive and highest level of care and treatment.
Scientific Research Overview
Scientific Investigators within the Radiation Oncology Branch (ROB) represent a critical mass of talent and expertise within the broad field of radiation oncology, from molecular and cellular biology to radiation biology and preclinical research, and imaging and clinical trials. Technological expertise in patient imaging, treatment, planning and delivery are essential to ensure that the innovative molecular and biological therapy is built upon a superior technical platform.
In order to meet this goal the ROB maintains close collaboration with the Molecular Therapeutics Section of the Imaging Sciences Program at the NCI as well as with other diagnostic imaging experts on staff within the clinical center.
The National Capital Consortium Radiation Oncology Residency Program
The Radiation Oncology Branch participates with the Walter Reed National Military Medical Center (WRNMMC) in the National Capital Consortium Radiation Oncology Residency Program sponsored by the University Services University of the Health Sciences. The Branch is a committed and active participant in this residency program and is dedicated to training radiation oncologists with the knowledge and skills necessary to optimize the role of radiation therapy for the treatment of patients in the post-human genome era.
-
A Phase I Clinical Trial of Selinexor (KPT-330) in Combination with Temozolomide and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma
Open - RecruitingNCI Protocol ID NCI-20-C-0027Investigator Kevin A. Camphausen, M.D. -
A Phase I Trial of Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
Open - RecruitingNCI Protocol ID NCI-18-C-0028Investigator Deborah E. Citrin, M.D. -
Phase I Trial of image guided focally dose escalated prostate SBRT for locally recurrent prostate cancer after prior radiotherapy
Open - RecruitingNCI Protocol ID NCI-17-C-0153Investigator Deborah E. Citrin, M.D. -
A Phase I Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
Open - RecruitingNCI Protocol ID NCI-16-C-0081Investigator Kevin A. Camphausen, M.D. -
Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided Biopsies
Open - RecruitingNCI Protocol ID NCI-13-C-0119Investigator Deborah E. Citrin, M.D.Share this trial: Referral ContactsContact Name Phone Number Deborah Citrin 301.496.5457 Theresa Cooley Zgela 301.451.8905 -
A Pilot Study of High Dose Rate Brachytherapy in The Radiation Oncology Branch#xD; #xD;
Open - RecruitingNCI Protocol ID NCI-09-C-0100Investigator Deborah E. Citrin, M.D. -
A Pilot Study to Evaluate Neuropsychological Outcome Measures and their Relationship with Prognosis in Patients Receiving Radiation Therapy for Brain Metastases
Open - RecruitingNCI Protocol ID NCI-08-C-0214Investigator DeeDee K. Smart, M.D., Ph.D. -
Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence
Open - RecruitingNCI Protocol ID NCI-04-C-0200Investigator Kevin A. Camphausen, M.D. -
Evaluation of Late Effects and Natural History of Disease in Patients Treated with Radiotherapy
Open - RecruitingNCI Protocol ID NCI-00-C-0074Investigator Kevin A. Camphausen, M.D.
There are no Open Positions at this time. Check back again later, or take a look at CCR's Careers page.
About
Our Mission
The Radiation Oncology Branch (ROB) exists to plan and conduct pre-clinical and clinical research on the biologic and therapeutic effects of radiation administrated alone or in combination with other modalities of treatment; to develop novel technology and imaging based approaches for radiation oncology; to investigate the natural history of disease to understand and evaluate means of diagnostic assessment for the purpose of optimizing treatment selections; and to provide radiation therapy as well as general oncology consultations for patients admitted to other NIH Clinical Research Center (CRC) clinical services, in a collaborative approach.
Clinical Research Overview
The Radiation Oncology Branch exists as part of the National Cancer Institute (NCI) Center for Cancer Research (CCR). The ROB designs and conducts pre-clinical and clinical research on the biologic and therapeutic effect of radiation therapy. The research clinical trials that the ROB develops and conducts involve novel technology and/or imaging based approaches to radiation therapy treatment. Within ROB Computer Tomography (CT) and Magnetic Resonance (MR) image fusion is a routine part of a patient treatment planning. The ROB also provides treatment via radiosurgery, intensity-modulated 3-D conformal radiotherapy (IMRT), real-time dose measurement, brachytherapy, and MR-guided procedures.
The ROB team of clinical investigators are board certified in radiation oncology. The ROB clinical team is comprised of radiation oncologists, physicists, dosimetrists, residents, research nurses, clinical staff nurses, clinical assistants, data managers and access to social workers. All of our staff have board certification or professionally appropriate certification and education for their field of expertise. As a team, the ROB is dedicated to conducting clinical trials based on sound translations research, while providing the highest possible clinical care for patients with various types of malignancies.
The ROB clinical staff collaborate with other clinical and laboratory investigators within the ROB, CCR, as well as other Institutes within the NIH, including National Heart Lung and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the National Institute on Aging (NIA). The ROB also provides consultative services to the entire CCR, collaborating with other clinical services to provide the most comprehensive and highest level of care and treatment.
Scientific Research Overview
Scientific Investigators within the Radiation Oncology Branch (ROB) represent a critical mass of talent and expertise within the broad field of radiation oncology, from molecular and cellular biology to radiation biology and preclinical research, and imaging and clinical trials. Technological expertise in patient imaging, treatment, planning and delivery are essential to ensure that the innovative molecular and biological therapy is built upon a superior technical platform.
In order to meet this goal the ROB maintains close collaboration with the Molecular Therapeutics Section of the Imaging Sciences Program at the NCI as well as with other diagnostic imaging experts on staff within the clinical center.
The National Capital Consortium Radiation Oncology Residency Program
The Radiation Oncology Branch participates with the Walter Reed National Military Medical Center (WRNMMC) in the National Capital Consortium Radiation Oncology Residency Program sponsored by the University Services University of the Health Sciences. The Branch is a committed and active participant in this residency program and is dedicated to training radiation oncologists with the knowledge and skills necessary to optimize the role of radiation therapy for the treatment of patients in the post-human genome era.
Clinical Trials
-
A Phase I Clinical Trial of Selinexor (KPT-330) in Combination with Temozolomide and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma
Open - RecruitingNCI Protocol ID NCI-20-C-0027Investigator Kevin A. Camphausen, M.D. -
A Phase I Trial of Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
Open - RecruitingNCI Protocol ID NCI-18-C-0028Investigator Deborah E. Citrin, M.D. -
Phase I Trial of image guided focally dose escalated prostate SBRT for locally recurrent prostate cancer after prior radiotherapy
Open - RecruitingNCI Protocol ID NCI-17-C-0153Investigator Deborah E. Citrin, M.D. -
A Phase I Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
Open - RecruitingNCI Protocol ID NCI-16-C-0081Investigator Kevin A. Camphausen, M.D. -
Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided Biopsies
Open - RecruitingNCI Protocol ID NCI-13-C-0119Investigator Deborah E. Citrin, M.D.Share this trial: Referral ContactsContact Name Phone Number Deborah Citrin 301.496.5457 Theresa Cooley Zgela 301.451.8905 -
A Pilot Study of High Dose Rate Brachytherapy in The Radiation Oncology Branch#xD; #xD;
Open - RecruitingNCI Protocol ID NCI-09-C-0100Investigator Deborah E. Citrin, M.D. -
A Pilot Study to Evaluate Neuropsychological Outcome Measures and their Relationship with Prognosis in Patients Receiving Radiation Therapy for Brain Metastases
Open - RecruitingNCI Protocol ID NCI-08-C-0214Investigator DeeDee K. Smart, M.D., Ph.D. -
Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence
Open - RecruitingNCI Protocol ID NCI-04-C-0200Investigator Kevin A. Camphausen, M.D. -
Evaluation of Late Effects and Natural History of Disease in Patients Treated with Radiotherapy
Open - RecruitingNCI Protocol ID NCI-00-C-0074Investigator Kevin A. Camphausen, M.D.
PI & Key Staff
Positions
There are no Open Positions at this time. Check back again later, or take a look at CCR's Careers page.
Contact Info
Center for Cancer Research
National Cancer Institute
Building 10, Room B2-3561
Bethesda, MD 20892
Ph: 301-496-5457